Search Results 461-470 of 17436 for alopecia
... alopecia. Patients who have endocrinopathies associated with prior immunotherapy treatment but which are controlled with replacement therapy are eligible ...
Unresolved adverse events ≥ Grade 2 from prior anticancer therapy, except for alopecia; Has ongoing hemolysis; Major surgery within ≤ 28 days prior to the ...
Patients with vitiligo or alopecia;; Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement;; Any chronic skin ...
Atopic dermatitis (eczema). Birthmarks, such as hemangioma and port-wine stain. Connective tissue disorders of the skin. Contact dermatitis. Dermatoses of ...
*Note: Any adverse events derived from these therapies must be ≤ Grade 2 prior to starting study therapy (exception: alopecia). Participating Mayo Clinic ...
All toxicities attributed to prior anti-cancer therapy other than nephropathy, neuropathy, hearing loss, alopecia and fatigue must have resolved to Grade 1 ...
... alopecia or other toxicities not considered a safety risk for the subject at the Investigator's discretion). 4. Subject has had major surgery within 14 days ...
0, except for alopecia. Patients with chronic but stable Grade 2 toxicities may be allowed to enroll after an agreement between the Investigator and Sponsor ...
... alopecia, nausea, and fatigue); Clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association class 3 or 4 congestive ...
0 toxicity (except alopecia and vitiligo) related to prior therapy; however, sensory neuropathy Grade ≤ 2 is acceptable. Clinically significant ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.